

23 January 2025

UPGRADE TO REVENUE GUIDANCE FOR FY 2025

Further to the Addendum to Investor Presentation dated 14 January 2025, Australian life sciences, pharmaceutical and consumer health products Company, **Bioxyne Limited (ASX:BXN)** ("Bioxyne" "Group" or the "Company") advises that its upgraded Revenue forecast for the year ended 30 June 2025 is increased to \$25,000,000.

Revenue for H1 FY2025 is ~\$12.6 million a 267% increase on the previous half.

The Company achieved a record second quarter trading for FY2025, continuing the outstanding result of its previous Q1 trading. This result was on the strength of.

- ✓ several major contracts,
- ✓ a growing customer base, and
- ✓ an expanding product range.

The Company anticipates delivering four consecutive quarters of positive cashflow generation in FY25 and delivery of positive EBITDA for H1 FY25 and full year FY25.

The standout in the Group continues to be Breathe Life Science (**BLS**) Australia, Australia's leading manufacturer and wholesaler of novel medicines, following the granting of its Good Manufacturing Practice (**GMP**) Licence to manufacture medical cannabis products (also Australia's first licence to manufacture Psilocybin and MDMA) by the Therapeutic Goods Administration (**TGA**) in February 2024.

Outlook

The Company is focussed on

- ✓ growing its manufacturing customer base,
- ✓ growing market share for its Dr Watson® branded pharmaceutical products in Australia,
- ✓ growing the Dr Watson branded health and wellness products in Europe, and
- ✓ the introduction of its proprietary *Lactobacillus fermentum* PCC® probiotic product into its existing global distribution channels.

The Company's current production order book continues to grow as it moves forward to scale up its operations while maintaining the high-quality standards that BLS has provided with its pharmaceutical-grade products to date.

This announcement has been approved for release by the Board.

For further information contact:

Sam Watson

Managing Director

Bioxyne Limited

sam@breathelifesciences.com

Guy Robertson

Chief Financial Officer

Bioxyne Limited

guy@bioxyne.com




Figure 3 – Bioxyne Activity Worldwide



For personal use only

About Bioxyne Ltd.

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8) in Australia.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in the Gold Coast (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacture of final dose form / finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in manufacturing scope and quality.

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow. Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- c) White label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- d) Research and development for third party customers; and
- e) Direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **Japan:** nolcbn.com
 - **Germany:** drwatsoncbd.de

Corporate: <https://bioxyne.com>

Australia: <https://bls.com.au>; <https://blsclinics.com.au>

International: <https://breathelifesciences.com>

